Cardiology Update

NOVEMBER 26, 2023

In light of the growing number of patients undergoing transcatheter aortic valve replacement (TAVR), there is an increasing demand for data regarding the management of failed TAVR procedures, including the possibility of a repeat TAVR intervention. vs. 19.0%, p=0.57), as well as stroke at 30 days (2.0% vs. 3.3%, p=0.18).

TAVR 52

TAVR Aortic valve Outcomes Aortic 52

DAIC

MARCH 12, 2024

A cost-effectiveness analysis demonstrates the positive economic value of transcatheter aortic valve replacement (TAVR) using Evolut TAVR compared to surgical aortic valve replacement (SAVR) for low-risk patients. The findings showed a strong economic benefit of Evolut TAVR for low-risk patients from a U.S.

TAVR 52

TAVR Aortic valve Aortic Stenosis 52

DAIC

MAY 1, 2024

According to the Centers for Disease Control and Prevention (CDC), heart disease and stroke rank as the first and fifth leading causes of death in the nation. About 276,000 patients have undergone a TAVR procedure in the United States.

Interventional Cardiology 105

Interventional Cardiology Aortic valve TAVR Peripheral Arterial Disease 105

American College of Cardiology

OCTOBER 29, 2024

In women with symptomatic, severe aortic stenosis (AS), TAVR with the balloon-expandable valve was superior to surgical aortic valve replacement in terms of the composite rate of death, stroke and rehospitalization at one-year follow-up, according to a pooled analysis of patient-level data from RHEIA and PARTNER 3 trials presented at TCT 2024.

TAVR 44

TAVR Aortic valve Aortic Stenosis 44

Circulation: Cardiovascular Interventions

MARCH 26, 2025

BACKGROUND:Current guidelines recommend surgical aortic valve replacement (SAVR) for patients with severe aortic stenosis and unfavorable iliofemoral access. Transcarotid transcatheter aortic valve replacement (TC-TAVR) has emerged as an alternative access in suboptimal transfemoral candidates, but no data exist comparing TC-TAVR and SAVR.

Aortic valve 40

Aortic valve Aortic Stenosis TAVR 40

American College of Cardiology

OCTOBER 29, 2024

The goal of the PROTECTED TAVR trial was to evaluate the efficacy of intraprocedural cerebral embolic protection (CEP) in reducing strokes among patients undergoing transfemoral TAVR for aortic stenosis.

Aortic valve 42

Aortic valve Aortic TAVR Strokes 42

Open Heart

MAY 12, 2023

Objective To evaluate whether transcatheter or surgical aortic valve replacement (TAVR or SAVR) affects clinical and haemodynamic outcomes in symptomatic patients with moderately-severe aortic stenosis (AS). Valve haemodynamics improved following TAVR (AVA 2.5±0.7 <aortic valve area (AVA)<1.5 cm 2 , 3.0<peak

Aortic valve 52

Aortic valve Aortic Stenosis TAVR 52

Coronary Artery Disease Journal

MAY 13, 2024

Objective To investigate the impact of prior coronary artery bypass grafting (CABG) and coronary lesion complexity on transcatheter aortic valve replacement (TAVR) outcomes for aortic stenosis. The CABG SYNTAX score did not influence the prognosis after TAVR. The median CABG SYNTAX score was 16 (interquartile range: 9.0–23),

Coronary Artery Bypass Graft 40

Coronary Artery Bypass Graft Aortic valve Aortic Stenosis 40

Circulation

OCTOBER 25, 2023

Background:The optimal treatment in patients with severe aortic stenosis (AS) and small aortic annulus (SAA) remains to be determined. Participants were 151 patients with severe AS and SAA (mean diameter &lt;23 mm) were randomized (1:1) to TAVR (n=77) vs SAVR (n=74), The primary outcome was impaired valve hemodynamics (i.e.

Aortic valve 40

Aortic valve Aortic TAVR Stenosis 40

Circulation

NOVEMBER 11, 2024

Seven studies showed that TAVR patients had a similar 1-year stroke risk to SAVR patients (OR 0.92, 95% CI 0.64 In the TIA case, there was no evidence of a significant difference between TAVR and SAVR in the risk of having a transient ischemic attack within 30 days following surgery (OR 0.93, 95% CI 0.24 to 1.17, p=0.30, I2 3%).

Aortic valve 40

Aortic valve Aortic TAVR Strokes 40

European Journal of Heart Failure

JANUARY 31, 2024

TAVR in heart failure. ABSTRACT Patients with severe aortic stenosis (AS) may develop heart failure (HF), the presence of which has traditionally been deemed as a final stage in AS progression with poor outcomes. The prognostic covariates and optimal timing of TAVR in patients with less than severe AS remain unclear.

Aortic valve 40

Aortic valve Heart Failure Aortic TAVR 40

Journal of Cardiovascular Pharmacology

NOVEMBER 21, 2023

Abstract: Transcatheter aortic valve replacement (TAVR) is an interventional procedure performed in patients with severe aortic stenosis and often required perioperative antiplatelet therapy. Most previous studies have focused on antiplatelet therapy following TAVR.

Aortic valve 40

Aortic valve Aortic TAVR Myocardial Infarction 40

Circulation

OCTOBER 23, 2023

Background: Atrial fibrillation (AF) is common in patients undergoing transcatheter aortic valve replacement (TAVR) and is associated with increased risk of bleeding and stroke. Patients were randomized 1:1 to TAVR+LAAO or TAVR+medical therapy. For the composite primary endpoint, TAVR+.LAAO compared to 50.8%

Aortic valve 40

Aortic valve Atrial Fibrillation TAVR Aortic 40

The British Journal of Cardiology

FEBRUARY 20, 2024

Patients with bicuspid aortic valves (BAV) are predisposed to the development of aortic stenosis. We performed a pairwise meta-analysis, comparing the efficacy of transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR) in patients with BAV. to 4.58, p=0.04).

Aortic valve 40

Aortic valve Bicuspid/Mitral Aortic TAVR 40

Circulation: Cardiovascular Interventions

OCTOBER 22, 2023

Background:Atherosclerotic cardiovascular disease (ASCVD) is highly prevalent in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). Exposure of interest was PVD. Primary outcome was all-cause mortality. 2VB-PVD, HR 1.12; 95% CI, 1.09-1.15, 1.15, and 3VB-PVD, HR 1.31; 95% CI, 1.26-1.36).

Aortic valve 40

Aortic valve Aortic TAVR Outcomes 40

Society of Thoracic Surgeons - Congenital

OCTOBER 17, 2023

The study matched the criterion used in the current low-risk trials evaluating SAVR with transcatheter aortic valve replacement (TAVR). The most recent mid-term results from the PARTNER 3 and Evolut Low-Risk trials comparing risk of death and stroke from SAVR and TAVR are expected to be released in fall 2023.

Aortic valve 40

Aortic valve TAVR Aortic Cardiothoracic 40

Cardiology Update

APRIL 9, 2024

SMART 4 ( NCT04722250 ) studied patients with severe aortic stenosis and a small aortic annulus who underwent transcatheter aortic valve replacement (TAVR). A total of 716 patients underwent TAVR with either a self-expanding supraannular valve or a balloon-expandable valve. vs. 6.2%) and stroke (2.9%

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

DAIC

FEBRUARY 29, 2024

24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Stroke Journal

JANUARY 30, 2025

Stroke, Volume 56, Issue Suppl_1 , Page ATP316-ATP316, February 1, 2025. Background:Despite improvements in the safety of transcatheter aortic valve replacement (TAVR), ~4% of patients experience a procedure-related stroke. We assessed if there was a difference in stroke events between cancer and non-cancer patients.

Aortic valve 40

Aortic valve Cancer Aortic Stenosis 40

DAIC

FEBRUARY 15, 2024

Transcatheter Mitral Valve Repair is Cost-Effective in Heart Failure Patients TAVR Expected to See Rapid Growth in Next 5 years FDA Clears Abbott Amplatzer Amulet LAA Occluder to Reduce Stroke in People With Atrial Fibrillation Portico TAVR System Found Safe and Effective for High-Risk Surgical Patients Portico TAVR System Reduces Severe (..)

Tricuspid 102

Tricuspid Heart Valves Quality of Life Bicuspid/Mitral 102

Open Heart

JULY 23, 2024

Objective To compare long-term cardiovascular (CV) outcomes between men and women with aortic stenosis (AS) undergoing aortic valve replacement (AVR) by the type of valve implant. In the TAVR cohort, men suffered a higher risk of death (HR: 1.24; 95% CI: 1.07 In the bioSAVR cohort, a higher risk of death (HR: 1.14; 95% CI: 1.04

Aortic valve 52

Aortic valve Aortic Stenosis TAVR 52

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

Society of Thoracic Surgeons - Research

APRIL 20, 2023

Mark Erfe 2 Outcomes of Sutureless/Rapid Deployment Valves Compared to Traditional Bioprosthetic Aortic Valves The Annals of Thoracic Surgery September 2020 Victor Nauffal 2 Short-Term Outcomes of Transcatheter Versus Isolated Surgical Aortic Valve Replacement for Mediastinal Radiation-Associated Severe Aortic Stenosis Circulation: Cardiovascular Interventions (..)

Research 52

Research Coronary Artery Bypass Graft Aortic valve Congenital 52

American College of Cardiology

OCTOBER 28, 2024

Findings from the TAVR UNLOAD trial found preemptive TAVR was not superior to clinical aortic stenosis surveillance (CASS) for the hierarchical occurrence of all-cause death, disabling stroke, disease-related hospitalizations and heart failure equivalents, and change in quality of life among patients with moderate aortic stenosis (AS) and heart failure (..)

TAVR 59

TAVR Quality of Life Heart Failure Stenosis 59

CardiacWire

NOVEMBER 3, 2024

This year’s TCT conference saw a deluge of TAVR studies examining everything from the efficacy of valve designs to TAVR’s impact on aortic and tricuspid regurgitation. Patients who received early TAVR were 16% less likely to experience MACE and saw better heart function over a median of 3.8

TAVR 59

TAVR Embolism Aortic Interventional Cardiology 59